NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Dyne Therapeutics, Inc. (DYN) Stock Analysis

Dyne Therapeutics, Inc. (DYN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

DYN

$16.07

−$0.20 (−1.23%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare DYN with… →

DYN Key Statistics

As of Oct 21, 2026
Trading
Open
$16.33
Previous Close
$16.27
Day's Range
15.91–16.73
52-Week Range
14.00–27.31
Volume
1.79M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.12
Valuation
Market Cap
$3.00B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.30
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$446.21M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
186.75M
1-Year Return
−4.06%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
3.00M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, DYN closed at $16.07, −4.06% over 1 year.

Dyne Therapeutics, Inc. (DYN) has a market capitalization of $3.00B.

In fiscal 2025, DYN reported revenue of $0.00.

DYN Stock Return by Calendar Year

Dyne Therapeutics, Inc. (DYN) return since Sep 2020: what $10,000 became

1 year
$10,000 $9,594
−4.06%
5 years
$10,000 $11,183
+11.83%
Since Sep 2020
$10,000 $6,724
−32.76%

If you had invested $10,000 in Dyne Therapeutics, Inc. (DYN) at the close on September 17, 2020, the earliest close on record here, it would have been worth $6,724 at the close on October 21, 2026: −32.76% in total, −6.31% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−17.84%
2025−16.98%
2024+77.14%
2023+14.75%
2022−2.52%
2021−43.38%
2020 (partial year)−12.13%

As of October 21, 2026.

DYN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$446.21M—
2024$0.00−$317.42M—
2023$0.00−$235.94M—
2022$0.00−$168.10M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$468.18M−$446.21M—
2024$0.00—−$343.89M−$317.42M—
2023$0.00—−$242.16M−$235.94M—
2022$0.00—−$170.96M−$168.10M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Dyne Therapeutics, Inc. (DYN) at $3.00B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 289 employees.

The 52-week range on file runs from $14.00 to $27.31. The most recent close on file for DYN is $16.07, dated October 21, 2026. That is −$0.20 (−1.23%) against the previous close. The latest close sits 14.79% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $446.21M. Trailing earnings per share are −3.3.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 1.12. Daily returns over the trailing 6 years annualize to a volatility of 77.77%. The trailing one-year total return is −4.06%. Across 5 years the annualized return works out at +2.26%.

Growth & Income

The record shows no dividend for DYN.

The strongest complete calendar year on file is 2024 at +77.14%; the weakest is 2021 at −43.38%. Of the 5 complete calendar years on file, 2 finished higher. So far in 2026 the total return is −17.84%.

Peer Comparison

Dyne Therapeutics, Inc. (DYN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Dyne Therapeutics, Inc. DYN $3.00B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Dyne Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Visit website →